Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

, NVS

Novartis

$83.78

-0.29 (-0.34%)

08:01
08/29/18
08/29
08:01
08/29/18
08:01

CyPass market removal a 'clear positive' for Glaukos, says William Blair

William Blair analyst Brian Weinstein believes Alcon's voluntary global market withdrawal of its CyPass Micro-Stent for surgical glaucoma is a "clear positive for near-term numbers" at Glaukos (GKOS). If Glaukos' iStent takes all of the CyPass market share while it is off the market, the company could add as much as $50M in the U.S. alone to its 2019 total revenue of around $186M, Weinstein tells investors in a research note, while admitting this is a bullish stance. The analyst thinks the news this morning from Alcon should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon. He keeps an Outperform rating on Glaukos shares.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

NVS

Novartis

$83.78

-0.29 (-0.34%)

  • 05

    Sep

  • 12

    Sep

GKOS Glaukos
$44.79

-0.64 (-1.41%)

08/24/18
WELS
08/24/18
NO CHANGE
Target $50
WELS
Outperform
Ivantis counterclaim against Glaukos looks weak, says Wells Fargo
Following a review by his firm's patent consultant, Wells Fargo analyst Larry Biegelsen says Ivantis' counterclaim, alleging that Glaukos' new iStent inject product will infringe three Ivantis patents, appears weak. The Ivantis patents very specifically add a detail about the placement of the shunt, which reads as "too straightforward" or "obvious," the patent consultant told the analyst. As such, he believes the patents will ultimately be found invalid. Biegelsen keeps an Outperform rating on Glaukos with a $50 price target.
08/13/18
PIPR
08/13/18
NO CHANGE
Target $46
PIPR
Overweight
Glaukos competitor received FDA approval on Friday, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien points out that privately-held Ivantis received FDA approval on Friday for its Hydrus stent to treat glaucoma. This should be a direct competitor to Glaukos' iStent, O'Brien tells investors in a research note. Though the timing of summer 2018 was expected, shares of Glaukos are likely to pull back today on the news, the analyst contends. O'Brien, however, does not expect too much of an impact on Glaukos sales from Ivantis given that the company still has to build out a commercial sales force and ensure proper training. In addition, the analyst believes "there is plenty of room for multiple players in this market." He remains constructive on Glaukos with an Overweight rating and $46 price target.
08/03/18
PIPR
08/03/18
NO CHANGE
Target $46
PIPR
Overweight
Glaukos price target raised to $46 from $38 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Glaukos to $46 citing the company's better than expected Q2 result. . The big news from the quarter is that Glaukos is pushing out the timing of iStent stand-alone by a couple years but accelerating the iDose by a year, O'Brien tells investors in a research note. He views the disclosure as a net neutral but expects the stock to trade down today. The analyst, however, believes the the pros outweigh the negatives and keeps a Overweight rating on Glaukos.
07/10/18
BMOC
07/10/18
DOWNGRADE
Target $44
BMOC
Market Perform
Glaukos downgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Joanne Wuensch downgraded Glaukos to Market Perform from Outperform but raised her price target to $44 from $42. The analyst notes that the stock price has risen 67% year-to-date, and its current valuation of 7.7-times enterprise value to next-twelve-month revenues will require an even more rapid revenue recovery than the anticipated 14.6% expected growth rate in FY19. Wuensh adds that the projected revenue growth is driven by the FDA approval of the company's iStent Inject, rising from 3.9% expected in FY18.
NVS Novartis
$83.78

-0.29 (-0.34%)

08/23/18
MSCO
08/23/18
NO CHANGE
Target $45
MSCO
Overweight
Pfizer price target raised to $45 from $43 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Pfizer (PFE) and raised his price target to $45 based upon a 5-year CAGR for revenue growth of 3% and EPS growth of 7%. In a research note to investors, Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Additionally, he notes that political news has been "encouraging" as of late, with President Trump tweeting on July 19 "Thank you to Novartis (NVS) for not increasing your prices on prescription drugs. Likewise to Pfizer." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
04/23/19
04/23
14:17
04/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
04/23/19
04/23
14:16
04/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$39.54

-0.17 (-0.43%)

14:12
04/23/19
04/23
14:12
04/23/19
14:12
On The Fly
Trump Effect: Harley points to tariff impact as Trump vows to 'reciprocate' »

Shares of Harley-Davidson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 09

    May

AG

First Majestic

$5.99

0.105 (1.78%)

14:05
04/23/19
04/23
14:05
04/23/19
14:05
Options
First Majestic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 10

    May

F

Ford

$9.45

0.105 (1.12%)

, AMZN

Amazon.com

$1,926.80

38.7 (2.05%)

14:02
04/23/19
04/23
14:02
04/23/19
14:02
Hot Stocks
Ford, Autonomic announce multi-year, global agreement with Amazon Web Services »

Ford Motor (F) and…

F

Ford

$9.45

0.105 (1.12%)

AMZN

Amazon.com

$1,926.80

38.7 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 22

    May

  • 03

    Jun

  • 24

    Jul

  • 23

    Oct

F

Ford

$9.46

0.115 (1.23%)

, AMZN

Amazon.com

$1,926.53

38.43 (2.04%)

14:01
04/23/19
04/23
14:01
04/23/19
14:01
Hot Stocks
Breaking Hot Stocks news story on Ford, Amazon.com »

Ford, Autonomic announce…

F

Ford

$9.46

0.115 (1.23%)

AMZN

Amazon.com

$1,926.53

38.43 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 03

    May

  • 09

    May

  • 10

    May

  • 22

    May

  • 03

    Jun

  • 24

    Jul

  • 23

    Oct

TWTR

Twitter

$39.82

5.43 (15.79%)

13:59
04/23/19
04/23
13:59
04/23/19
13:59
Recommendations
Twitter analyst commentary at Baird »

Twitter price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 20

    May

ADNT

Adient

$25.11

-0.43 (-1.68%)

13:55
04/23/19
04/23
13:55
04/23/19
13:55
Options
Adient put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

TNXP

Tonix Pharmaceuticals

$2.29

-0.035 (-1.51%)

13:54
04/23/19
04/23
13:54
04/23/19
13:54
Hot Stocks
Tonix Pharmaceuticals says USAMMDA exercising right to terminate CRADA »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

TNXP

Tonix Pharmaceuticals

$2.29

-0.035 (-1.51%)

13:52
04/23/19
04/23
13:52
04/23/19
13:52
Hot Stocks
Breaking Hot Stocks news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AGN

Allergan

$142.87

2.6 (1.85%)

, TEVA

Teva

$15.14

0.435 (2.96%)

13:50
04/23/19
04/23
13:50
04/23/19
13:50
Conference/Events
Piper Jaffray specialty pharma analysts to hold analyst/industry conference call »

Specialty Pharmaceuticals…

AGN

Allergan

$142.87

2.6 (1.85%)

TEVA

Teva

$15.14

0.435 (2.96%)

ALDR

Alder Biopharmaceuticals

$13.55

0.78 (6.11%)

AMGN

Amgen

$180.01

3.81 (2.16%)

BHVN

Biohaven Pharmaceutical

$63.34

2.39 (3.92%)

LLY

Eli Lilly

$117.60

2.16 (1.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 21

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

TWTR

Twitter

$39.95

5.56 (16.17%)

13:44
04/23/19
04/23
13:44
04/23/19
13:44
Recommendations
RBC 'more constructive' on Twitter post results, boosts price target to $38 »

In a post-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 20

    May

BRFS

BRF S.A.

$7.54

0.44 (6.20%)

13:40
04/23/19
04/23
13:40
04/23/19
13:40
Options
Renewed call buying in BRF SA as shares rally 6.5% »

Renewed call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PW

Power REIT

$5.74

-0.075 (-1.29%)

13:39
04/23/19
04/23
13:39
04/23/19
13:39
Hot Stocks
Cascadilla Capital Partners urges sale or liquidation of Power REIT »

Todd Merkle, Managing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$31.44

1.21 (4.00%)

13:36
04/23/19
04/23
13:36
04/23/19
13:36
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 08

    May

MBRX

Moleculin Biotech

$1.60

-1.37 (-46.13%)

13:35
04/23/19
04/23
13:35
04/23/19
13:35
Hot Stocks
Sabby Management reports 7.14% passive stake in Moleculin Biotech »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LMT

Lockheed Martin

$336.62

21.38 (6.78%)

13:31
04/23/19
04/23
13:31
04/23/19
13:31
Hot Stocks
Lockheed Martin receives $362M contract for MLRS launchers »

The U.S. Army awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 29

    May

  • 05

    Jun

13:30
04/23/19
04/23
13:30
04/23/19
13:30
General news
Treasury Action: yields remain lower after a well received 2-year auction »

Treasury Action: yields…

TCEHY

Tencent

$0.00

(0.00%)

, KKR

KKR

$23.76

0.33 (1.41%)

13:28
04/23/19
04/23
13:28
04/23/19
13:28
Periodicals
Epic workers describe 'Fortnite' working environment as toxic, Polygon says »

Current and former…

TCEHY

Tencent

$0.00

(0.00%)

KKR

KKR

$23.76

0.33 (1.41%)

DIS

Disney

$133.00

1.3 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 08

    May

  • 15

    May

  • 11

    Jun

TSLA

Tesla

$264.55

1.65 (0.63%)

13:26
04/23/19
04/23
13:26
04/23/19
13:26
Hot Stocks
Tesla electric vehicle challenger Lucid Motors appoints Peter Rawlinson as CEO »

Electric car start-up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

PAGS

PagSeguro Digital

$26.03

0.375 (1.46%)

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Options
PagSeguro Digital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.37

4.14 (1.52%)

, CRM

Salesforce

$160.44

1.69 (1.06%)

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Conference/Events
Stephens eCommerce analysts to hold an analyst/industry conference call »

Analysts provide an…

ADBE

Adobe

$276.37

4.14 (1.52%)

CRM

Salesforce

$160.44

1.69 (1.06%)

SHOP

Shopify

$223.04

-1.28 (-0.57%)

SAP

SAP

$114.13

0.36 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 30

    Apr

  • 07

    May

  • 08

    May

  • 03

    Jun

  • 23

    Jun

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Conference/Events
The Board of Governors of the Federal Reserve System to hold a meeting »

The Board of Governors of…

DNLI

Denali Therapeutics

$24.10

-0.74 (-2.98%)

13:25
04/23/19
04/23
13:25
04/23/19
13:25
Conference/Events
Denali Therapeutics participates in a conference call with JPMorgan »

SMid Biotech Analyst Fye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
04/23/19
04/23
13:17
04/23/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.